文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

致死性COVID-19与急性呼吸窘迫综合征中的血管病变及血管充血增加

Vasculopathy and Increased Vascular Congestion in Fatal COVID-19 and Acute Respiratory Distress Syndrome.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01
一句话结论尸检比较显示致死性COVID-19肺炎较其他原因DAD存在更显著血管病变与肺泡间隔充血,且充血与更短生存、更高通气比相关。

该尸检队列连续纳入COVID-19肺炎20例与呼吸衰竭伴组织学DAD21例(非COVID-19病毒及非病毒病因),比较生前的胸部CT血管改变与死后肺组织的组织病理和计算分析,并用机器学习衍生的形态学分析结合随机森林分类器量化不同显微间室的血管充血。生前CT显示COVID-19患者在所有肺段评估时血管更扩张(P=0.001);组织病理显示血管瘤样改变(P=0.043)、血栓栓塞(P=0.0038)、肺梗死(P=0.047)及血管周围炎症(P<0.001)。广义估计方程显示所有DAD病因间肺微结构存在显著区域差异,COVID-19总体CVasc范围更大(P=0.002)。在所有ARDS病例中,肺泡间隔充血与症状出现至死亡时间更短(P=0.03)、住院时间更短(P=0.02)及通气比升高(P=0.043)相关。结论认为重型COVID-19肺炎以显著血管病变和异常肺泡间隔充血为特征,血管改变可能在ARDS的死腔分数与临床结局中起作用。

要点

  • 尸检队列中,COVID-19肺炎20例与非COVID-19 DAD 21例比较,生前CT所有肺段评估显示COVID-19血管更扩张(P=0.001)。
  • 组织病理显示COVID-19较对照更多血管瘤样改变(P=0.043)、血栓栓塞(P=0.0038)、肺梗死(P=0.047)及血管周围炎症(P<0.001)。
  • COVID-19总体CVasc范围更大(P=0.002),广义估计方程显示所有DAD病因间肺微结构存在显著区域差异。
  • 所有ARDS病例中,肺泡间隔充血与症状出现至死亡时间更短(P=0.03)、住院时间更短(P=0.02)及通气比升高(P=0.043)相关。

适用人群与场景

  • 尸检队列连续纳入COVID-19肺炎患者(n=20)及呼吸衰竭伴组织学DAD的非COVID-19患者(n=21;非COVID-19病毒及非病毒病因)。

研究设计与关键结果

  • 研究类型为尸检队列,比较COVID-19肺炎(n=20)与非COVID-19 DAD(n=21)的肺实质与血管改变。
  • 生前胸部CT在所有肺段评估时,COVID-19患者血管更扩张(P=0.001)。
  • 组织病理显示血管瘤样改变(P=0.043)、血栓栓塞(P=0.0038)、肺梗死(P=0.047)及血管周围炎症(P<0.001)。
  • 广义估计方程显示所有DAD病因间肺微结构存在显著区域差异;COVID-19总体CVasc范围更大(P=0.002)。
  • 在所有ARDS病例中,肺泡间隔充血与症状出现至死亡时间更短(P=0.03)、住院时间更短(P=0.02)及通气比升高(P=0.043)相关。

证据类型、等级与局限

  • 证据类型:尸检队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,重型COVID-19肺炎以显著血管病变和异常肺泡间隔充血为特征,血管改变可能在ARDS的死腔分数与临床结局中起作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: The leading cause of death in coronavirus disease 2019 (COVID-19) is severe pneumonia, with many patients developing acute respiratory distress syndrome (ARDS) and diffuse alveolar damage (DAD). Whether DAD in fatal COVID-19 is distinct from other causes of DAD remains unknown. Objective: To compare lung parenchymal and vascular alterations between patients with fatal COVID-19 pneumonia and other DAD-causing etiologies using a multidimensional approach. Methods: This autopsy cohort consisted of consecutive patients with COVID-19 pneumonia (n = 20) and with respiratory failure and histologic DAD (n = 21; non-COVID-19 viral and nonviral etiologies). Premortem chest computed tomography (CT) scans were evaluated for vascular changes. Postmortem lung tissues were compared using histopathological and computational analyses. Machine-learning-derived morphometric analysis of the microvasculature was performed, with a random forest classifier quantifying vascular congestion (CVasc) in different microscopic compartments. Respiratory mechanics and gas-exchange parameters were evaluated longitudinally in patients with ARDS. Measurements and Main Results: In premortem CT, patients with COVID-19 showed more dilated vasculature when all lung segments were evaluated (P = 0.001) compared with controls with DAD. Histopathology revealed vasculopathic changes, including hemangiomatosis-like changes (P = 0.043), thromboemboli (P = 0.0038), pulmonary infarcts (P = 0.047), and perivascular inflammation (P < 0.001). Generalized estimating equations revealed significant regional differences in the lung microarchitecture among all DAD-causing entities. COVID-19 showed a larger overall CVasc range (P = 0.002). Alveolar-septal congestion was associated with a significantly shorter time to death from symptom onset (P = 0.03), length of hospital stay (P = 0.02), and increased ventilatory ratio [an estimate for pulmonary dead space fraction (Vd); p = 0.043] in all cases of ARDS. Conclusions: Severe COVID-19 pneumonia is characterized by significant vasculopathy and aberrant alveolar-septal congestion. Our findings also highlight the role that vascular alterations may play in Vd and clinical outcomes in ARDS in general.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Villalba JA, Hilburn CF, Garlin MA, et al. Vasculopathy and Increased Vascular Congestion in Fatal COVID-19 and Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2022. PMID: 35671465. doi:10.1164/rccm.202109-2150OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。